Scottish HTA OKs Neratinib For Early-Stage Breast Cancer
Treatment Fills An Unmet Need, Say Clinical Experts
A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.
You may also be interested in...
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.
The European Medicines Agency's drug evaluation committee, the CHMP, has recommended nine products for marketing authorization in the EU, including the first two CAR T-cell therapies, Novartis's Kymriah and Kite Pharma's Yescarta, as well as four other orphan drugs.
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.